VIR ▲ +5.4% - Vir Biotechnology, Inc.
$VIR Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
05-OCT-2026 04:05 PM ET
Share this post
More filings for $VIR
VIR ▼ -20.0% - Vir Biotechnology, Inc.Nov 12, 2026VIR - Vir Biotechnology, Inc. - SEC Filing Update (10-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 10, 2026VIR ▲ +16.9% - Vir Biotechnology, Inc.Nov 9, 2026VIR - Vir Biotechnology, Inc. - SEC Filing Update (06-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 7, 2026VIR - Vir Biotechnology, Inc. - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026VIR ▲ +11.7% - Vir Biotechnology, Inc.Oct 14, 2026
View full $VIR filing history →💬 Comments
Loading comments…
Leave a comment